Endo eyes a deal for Somerset and Wintac
Executive Summary
Endo is set to augment the firm’s commercial portfolio and pipeline of generic sterile injectables and ophthalmic drugs, as well as bolster its manufacturing capabilities, after agreeing to acquire New Jersey based Somerset Therapeutics and its contract development and manufacturing business, India’s Wintac, for around US$190 million.
You may also be interested in...
Endo Breaks Off Deal To Acquire Somerset And Wintac
Endo has announced that it will not pursue a previously-announced US$190 million deal to augment its injectables portfolio and pipeline by acquiring Somerset Therapeutics and its India-based Wintac contract development and manufacturing business. The news comes as Endo has reported US generics sales down by a third – and total turnover down by 15% – in 2018.
Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.
US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla
Despite winning a landmark multi-billion-dollar antitrust suit earlier this year, Gilead Sciences has seen a US court give an initial green light allowing it to shell out nearly $250m to settle antitrust claims from direct purchasers of its two major HIV drugs.